Phenotypes Associated with This Genotype

Genotype
MGI:4452388

• Allelic Composition: Tg(CYP1A1-PPARD)#Jfoe/0
• Genetic Background: involves: C57BL/6J * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Psoriasis-like skin disease in Tg(CYP1A1-PPARD)#Jfoe/0 mice 20 days after GW501516 administration

immune system

increased T cell proliferation ( J:158907 )

• GW501516-treated mice exhibit expansion of Th17 cells unlike in similarly treated wild-type mice

• however, injection of anti-IL12/23p40 and to a lesser extent anti-TNFalpha suppresses expansion of Th17 cells and reduces skin disease severity

skin inflammation ( J:158907 )

• GW501516-treated mice exhibit skin inflammation with abundant lymphocytes and Th17 cells in the epidermis unlike in similarly treated wild-type mice

• however, injection of anti-IL12/23p40 and to a lesser extent anti-TNFalpha suppresses expansion of Th17 cells and reduces skin disease severity

hematopoietic system

increased T cell proliferation ( J:158907 )

• GW501516-treated mice exhibit expansion of Th17 cells unlike in similarly treated wild-type mice

• however, injection of anti-IL12/23p40 and to a lesser extent anti-TNFalpha suppresses expansion of Th17 cells and reduces skin disease severity

integument

integument phenotype ( J:158907 )

N • indole-3-carbinole (I3C)-treated mice have a normal skin phenotype

increased keratinocyte proliferation ( J:158907 )

• in GW501516-treated mice

skin inflammation ( J:158907 )

• GW501516-treated mice exhibit skin inflammation with abundant lymphocytes and Th17 cells in the epidermis unlike in similarly treated wild-type mice

• however, injection of anti-IL12/23p40 and to a lesser extent anti-TNFalpha suppresses expansion of Th17 cells and reduces skin disease severity

alopecia ( J:158907 )

• GW501516-treated mice exhibit hair loss particularly in regions of mechanical friction unlike in wild-type mice

abnormal skin morphology ( J:158907 )

• topical application of I3C and GW501516 exhibit skin diseases

• however, injection of anti-IL12/23p40 and to a lesser extent anti-TNFalpha suppresses expansion of Th17 cells and reduces skin disease severity

abnormal dermal layer morphology ( J:158907 )

• GW501516-treated mice exhibit dilated dermal vessels unlike in wild-type mice

hyperkeratosis ( J:158907 )

• in GW501516-treated mice

thick epidermis ( J:158907 )

• in GW501516-treated mice

abnormal skin appearance ( J:158907 )

• GW501516-treated mice exhibit scaling, inflammation, and skin thickening unlike in similarly treated wild-type mice

scaly skin ( J:158907 )

• in GW501516-treated mice

psoriasis ( J:158907 )

• in some GW501516-treated mice

thick skin ( J:158907 )

• in GW501516-treated mice

cellular

increased T cell proliferation ( J:158907 )

• GW501516-treated mice exhibit expansion of Th17 cells unlike in similarly treated wild-type mice

• however, injection of anti-IL12/23p40 and to a lesser extent anti-TNFalpha suppresses expansion of Th17 cells and reduces skin disease severity

increased keratinocyte proliferation ( J:158907 )

• in GW501516-treated mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
psoriasis		DOID:8893	OMIM:PS177900	J:158907